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Oestrogen receptor (ER) and progesterone receptor (PgR) status
are determined in breast cancer cytosol to predict both the
response to endocrine therapy (Osborne et al, 1980) and the likeli-
hood of recurrence (Clark et al, 1988). However, only 50–70% of
ER-positive (ER+) tumours respond to anti-hormone therapy, and
steroid receptor status is a relatively short-term prognostic factor.
Recent studies have investigated the clinical value of pS2 as an
additional marker of hormone response (Henry et al, 1989;
Schwartz et al, 1991; Spyratos et al, 1994) and of cathepsin D
(Cath D) as a prognostic factor in breast cancer (Tandon et al,
1990; Rochefort et al, 1992; Pujol et al, 1993).
There is currently considerable interest in the time of surgery
according to the phase of the menstrual cycle in terms of tumour
biology (Badwe et al, 1995; Oliver et al, 1995; Holdaway et al,
1997) and prognosis (Senie et al, 1991; Fentiman et al, 1994;
Veronesi et al, 1994; Mohr et al, 1996). Some studies suggested
that ER levels in human breast cancer underwent changes
throughout the menstrual cycle, with an overall trend towards a
higher ER level in the follicular phase (Coradini et al, 1984; Holli
et al, 1995, Pujol et al, 1998).
Cath D is an ubiquitous lysosomal proteinase. Its overexpres-
sion in breast cancer tissues has been correlated to poor prognosis,
independently of other prognostic factors (Rochefort et al, 1992;
Ferrandina et al, 1997). In contrast, a high pS2 level is an indicator
of good prognosis and of hormone sensitivity, and is generally
correlated to steroid receptor positivity (Foekens et al, 1990). Both
pS2 and Cath D proteins have been shown to be oestrogen induced
in ER+ breast cancer cell lines (Westley et al, 1980; Masiakowski
et al, 1982). Cath D and pS2 might, thus, be regulated throughout
the menstrual cycle in breast tumours.
The possible variations of pS2 and Cath D according to the
hormonal state raises important questions on the clinical interpre-
tation of these markers in terms of prognosis or hormone depen-
dency, particularly whether it is appropriate to use the same cut-off
throughout the reproductive life and menopause. We studied rela-
tionships between pS2, Cath D and the hormonal phase, as deter-
mined by levels of circulating hormones, in a large population of
breast cancer patients.
PATIENTS AND METHODS
Patients
Patients with primary breast cancer (1750) were included in a
monocentric prospective study from 1988 to 1994 (Cancer Centre
of Montpellier, France). All the patients have circulating hormone
analyses from a blood sample obtained on the day of surgery. Oral
consent was obtained for all patients. Exclusion criteria were
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Summary Many studies have addressed the clinical value of pS2 as a marker of hormone responsiveness and of cathepsin D (Cath D) as a
prognostic factor in breast cancer. Because pS2 and Cath D are both oestrogen induced in human breast cancer cell lines, we studied the
influence of the menstrual cycle phase and menopausal status at the time of surgery on the levels of these proteins in breast cancer. A
population of 1750 patients with breast cancer, including 339 women in menstrual cycle, was analysed. Tumoral Cath D and pS2 were
measured by radioimmunoassay. Serum oestradiol (E2), progesterone (Pg), follicle-stimulating hormone (FSH) and luteinizing hormone (LH)
levels at the day of surgery were used to define the hormonal phase in premenopausal women. There was a trend towards a higher mean
pS2 level in the follicular phase compared with the luteal phase (17 ng mg–1 and 11 ng mg–1 respectively, P = 0.09). Mean pS2 was lower in
menopausal patients than in women with cycle (8 ng mg–1 and 14 ng mg–1 respectively, P = 0.0001). No differences in mean Cath D level were
observed between the different phases of the menstrual cycle, or between pre- and post-menopausal women. In the overall population, pS2
was slightly positively associated with E2 and Pg levels and negatively associated with FSH and LH, probably reflecting the link between pS2
and menopausal status. In premenopausal women, no association was found between pS2 and E2, Pg, FSH or LH levels. There were no
correlations between Cath D level and circulating hormone levels in the overall population. However, in the subgroup of premenopausal
women with ER-positive (ER+) tumours, E2 was slightly associated with both pS2 and Cath D, consistent with oestrogen induction of these
proteins in ER+ breast cancer cell lines. There are changes in pS2 level in breast cancer throughout the menstrual cycle and menopause.
This suggests that the choice of the pS2 cut-off level should take the hormonal status at the time of surgery into account. In contrast, the level
of Cath D is unrelated to the menstrual cycle and menopausal status.
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Giraud, 34295 Montpellier, Francepreoperative radiotherapy, neoadjuvant chemotherapy or tamox-
ifen therapy, use of oral contraceptives less than 1 month before
surgery, hormone replacement therapy and pregnancy.
Hormonal status was defined as follows: premenopausal, patients
with regular menstrual cycle (n = 339); menopausal, patients with
the last regular menses occurring more than 2 years earlier (post-
menopausal, n = 1273) or less than 2 years earlier (perimenopausal,
n = 138). The hormonal phase of the menstrual cycle in
premenopausal patients was determined according to levels of circu-
lating hormones on the day of surgery, including E2 and Pg, follicle-
stimulating hormone (FSH) and luteinizing hormone (LH). Women
with progesterone values exceeding 2.5 ng ml–1 were considered to
be in the luteal phase of the cycle (n = 175). The ovulatory period
was defined on the basis of both high LH (>10 IU l–1) and oestradiol
(> 100 pg ml–1) values (n = 28). The remaining premenopausal
women were classified in the follicular phase (n = 136). The
precise date of the last menstrual period was available in 240
premenopausal patients.
Cytosolic assays
ER and PgR were assayed using the dextran-coated charcoal
method (Korenman et al, 1969) with [3H]oestradiol and [3H]pro-
gesterone (specific activity, 87 Ci mmol–1, NEN, Paris, France).
Protein concentration was assayed using the Lowry technique
(Lowry et al, 1951). Quality control included both internal
controls and EORTC standards. ER or PgR levels of 10 fmol mg–1
protein or more were considered positive. Total Cath D and pS2
were measured using immunoradiometric assays (ELSA-cathD
and ELSA-pS2 kit, respectively, CIS Bio-Industries, Gif-sur-
Yvette, France). Both Cath D and pS2 assays were routinely and
prospectively performed in our laboratory. Cath D level was avail-
able in all 1750 patients, whereas pS2 level, assayed from 1992 to
the end of the study, was performed in a subgroup of the last 652
consecutive patients.
Circulating hormones
Circulating hormones were assessed routinely in the laboratory of
our Cancer Centre from a blood sample obtained on the day of
surgery. Sera analyses were performed weekly, blinded of clinical
information. E2 and Pg were measured using two commercially
available radioimmunoassay kits, ESTR-US-CT and PROG-
CTRIA (CIS). LH and FSH were assessed using immunoradio-
metric [125I]hLH Coatria and [125I]hFSH Coatria kits, respectively
(Biomérieux, Marcy-l’Etoile, France). Oestrogen and proges-
terone levels are given in pg ml–1 and ng ml–1 respectively. FSH
and LH levels are given in mU ml–1.
Statistical analysis
The Mann–Whitney test or the Kruskall–Wallis test were used to
compare non-Gaussian quantitative parameters. Chi-squared or
Fisher tests were used to compare receptor positivity frequencies.
Correlations between quantitative parameters were analysed with
Spearman’s test. Multiple tests comparison were performed using the
Bonferroni method. The significance level (P-value) was set at 0.05.
RESULTS
pS2 and Cath D according to the menstrual cycle phase
and menopause
The mean pS2 level was higher in the follicular than in the luteal
phases (16.8 ng mg–1 and 10.9 ng mg–1 respectively, Figure 1A),
although the difference was not significant (P = 0.09). No changes
in Cath D were observed between the different phases of the
menstrual cycle (Figure 1B).
To study the effect of menopausal status on pS2 and Cath D
levels, the follicular, ovulatory and luteal phases were grouped
(premenopausal women), and compared with the group of both
peri- and post-menopausal women. The mean pS2 level was
higher in premenopausal women than in menopausal women
(14.4 ng mg–1 and 8.1 ng mg–1 respectively, P = 0.0001), whereas
no differences in Cath D levels were noted between premenopause
and menopause.
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Table 1 Correlations between Cath D, pS2 and circulating hormones.
(A) Overall population; (B) premenopausal women
A
E2 Pg FSH LH
Cath D –0.01* –0.01 –0.01 –0.01
(n = 1750) NS NS NS NS
pS2 0.15 0.13 –0.16 –0.10
(n = 652) 0.0002 0.001 <0.0001 0.01
B
E2 Pg FSH LH
Cath D 0.11 0.02 –0.03 0.03
(n = 339) 0.04 NS NS NS
pS2 0.10 –0.10 –0.02 0.16
(n = 133) NS NS NS NS
*Spearman rank correlation coefficient. P-value is indicated in italic; NS, not
significant.
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Figure 1 pS2 and Cath D levels according to the menstrual cycle phase
and menopause. Hormonal statuses were determined according to the levels
of circulating hormones as described in Patients and methods. foll, follicular
phase; ov, ovulatory period; lut, luteal phase; periM, premenopause; postM,
post menopause. Bars represent standard errors of the means. *Multiple test
comparison (Kruskall–Wallis non-parametric Anova test). **Follicular vs luteal
phase. NS, non-significant. (A) Mean pS2 level according to the hormonal
status. (B) Mean Cath D level according to the hormonal statusCorrelations between pS2, Cath D and circulating
hormones
In the overall population, pS2 was positively correlated with E2
and Pg levels and negatively correlated with FSH and LH (Table
1A). However, these associations between pS2 and circulating
hormones levels, although statistically significant using Spearman
rank correlation (<0.05), were weak as shown by the regression
coefficient (r). In premenopausal women, no associations were
found between pS2 and circulating hormone levels (Table 1B).
There was no correlation between Cath D and levels of E2, Pg,
FSH and LH in the overall population (Table 1A). In
premenopausal women, Cath D was weakly associated with E2
(Table 1B).
pS2, Cath D and circulating hormones according to ER
status
Because pS2 and Cath D proteins can be oestrogen induced via the
ER in breast cancer cell lines, we stratified the population of
premenopausal women according to ER status (Table 2). Mean
Cath D and pS2 levels were higher in ER+ than in ER– tumours
(P < 0.001 for both). The mean pS2 and Cath D levels according to
the hormonal phase in both ER+ and ER– tumours are shown in
Figure 2.
ER positivity decreased during the menstrual cycle (P = 0.03,
Table 2). Pg and E2 were slightly higher in ER– than in ER+
tumours. In the subgroup of premenopausal women with ER+
tumours, E2 was slightly correlated with both pS2 and Cath D
(r = 0.23 for both, data not shown).
Characteristics of patients according to pS2 and Cath D
status
Table 3 shows the characteristics of patients according to pS2
status as defined by a cut-off value of 2.5 ng mg–1 (median value).
pS2 status was positively related to ER, PgR and Cath D levels and
influenced by the hormonal status. When the median Cath D value
was used as a cut-off value (26 pmol mg–1), Cath D was positively
associated with both ER and PgR (P < 0.0001 for both, Table 4).
pS2 was higher in the group with Cath D levels greater than the
cut-off level (P = 0.01). Cath D status was not related to the
hormonal status nor to circulating sex hormones.
Correlations between pS2, Cath D and steroid
receptors
In the overall population, there was a correlation between pS2
and Cath D, but the regression coefficient was low (r = 0.14,
P < 0.001). Cath D was weakly associated with both ER and PgR
(r = 0.26 and r = 0.22 respectively; P < 0.0001 for both). pS2
was also weakly associated with both ER and PgR (r = 0.24 and
r = 0.40 respectively; P < 0.0001 for both). In the subgroup of
premenopausal women, these correlations between all cytosolic
proteins were also noted (data not shown).
Histopathological grade
Seven hundred and thirty-nine patients were analysed to correlate
Scraff Bloom and Richardson grade (SBR) with pS2, Cath D, ER,
PgR, E2, Pg and hormonal status. pS2 was slightly negatively
correlated with SBR grade (P = 0.03 respectively, Table 3),
whereas Cath D was positively correlated with SBR grade
(P < 0.0001, Table 4). The percentage of ER-positive tumours was
inversely associated with SBR grade (73% in grade I, 69% in
grade II and 51% in grade III, P < 0.001, data not shown). The
percentage of PgR-positive tumours was also lower in grade III
pS2, cathepsin D and hormones in breast cancer 911
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Table 2 Characteristics of patients according to ER status
Parameter ER– ER+ P-value
(mean) (n = 751) (n = 999)
Cath D 29 43 <0.001
(pmol mg–1)
pS2 7a 19b <0.0001
(ng mg–1)
RP 39 190 <0.001
(fmol mg–1)
E2 81 71 NS
(pg ml–1)
Pg 2.7 2.0 0.04
(ng ml–1)
Hormonal status
Follicular 58 (43) 78 (57) 0.03*
Ovulatory 13 (46) 15 (54)
Luteal 96 (55) 79 (45)
Menopausal 584 (41) 827 (59) NS**
Mean values. Numbers in parentheses are percentages. an = 234; bn = 418.
*Chi-squared for trend between follicular, ovulatory and luteal phases.
**Chi-squared for trend between all subgroups.
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Figure 2 Mean pS2 and Cath D levels according to the ER status.
(A) Mean pS2 in ER– tumours. (B) Mean pS2 in ER+ tumours. (C) Mean
Cath D in ER– tumours. (D) Mean Cath D in ER+ tumours(56%) than in grade I (64%) or II (68%, P = 0.02). E2, Pg, FSH,
LH and hormonal status were not related to SBR.
DISCUSSION
Cath D and pS2 have recently been analysed as markers of prog-
nosis or hormone dependency in breast cancer (Henry et al, 1989;
Foekens et al, 1990; Tandon et al, 1990; Schwartz et al, 1991;
Rochefort et al, 1992; Pujol et al, 1993; Spyratos et al, 1994).
Therefore, determinations of these markers at surgery could theo-
retically be proposed to guide clinicians in adjuvant therapy.
Although there is growing interest in the effect of the menstrual
cycle at time of surgery on the breast cancer prognosis, little is
known on the influence of the hormonal milieu at surgery on these
factors. We found that pS2, but not Cath D level, is affected by the
menstrual cycle phase and menopausal status at the time of surgery.
Cath D is secreted under the influence of oestrogen in ER+
breast cancer cell lines, but is also constitutively expressed in
oestrogen unresponsive breast cancer cell lines (Westley and
Rochefort, 1980). In ER+ premenopausal women, we found a
weak association between Cath D and E2, suggesting that E2
could in vivo stimulate Cath D expression by breast cancer cells.
This is consistent with previous data showing that tamoxifen
increases the Cath D level in ER+ patients, probably by acting
through its partial agonist oestrogenic effect (Maudelonde et al,
1994). However, we found no change in Cath D expression
during the menstrual cycle and menopause, indicating that this
marker could be interpreted in clinics independently of the
hormonal status.
In contrast, we found a decreased level of pS2 in the luteal phase
compared with the follicular phase, and in premenopausal women
compared with menopausal women. In the overall population, pS2
was weakly positively correlated with FSH and LH levels and
negatively to E2 and Pg. This is probably because of the correlation
between pS2 and menopausal status that was noted in our study as
in previous reports (Foekens et al, 1990; Predine et al, 1992;
Spyratos et al, 1994) because, in premenopause, no correlations
were found between E2, Pg, gonadotrophin and pS2. However, in
the subset of ER+ premenopausal women, pS2 was correlated with
the E2 level, suggesting that pS2 expression, like Cath D, could be
increased by E2 in some ER+ breast tumours.
As reported in previous studies, we noted a correlation between
pS2 and ER and PgR (Foekens et al, 1990; Predine et al, 1992;
Spyratos et al, 1994). There was also a weak association of Cath D
with both ER and PgR, as already found in several studies (Cazin
et al, 1993; Gion et al, 1995), but not all (Granata et al, 1991). This
study also confirmed the association of high Cath D level with
SBR grade II and III previously reported (Cazin et al, 1993; Gion
et al, 1995), as well as its correlation to pS2 (Gion et al, 1995).
To our knowledge, there is only one other published study on
the variation of pS2 and Cath D protein levels during the
menstrual phase and menopause (Khan et al, 1997). This study,
analysing pS2 and Cath D expression in 69 premenopausal
women, also noted no variation of Cath D throughout the cycle.
However, the authors found an increased pS2 level in the luteal
phase contrasting with our results. This discrepancy may be
explained by the difference in methods of pS2 and Cath D deter-
minations [immunohistochemistry in the study by Khan et al
(1997) and radioimmunoassay in the present study], and the
definition of the hormonal phases [menstrual history in the
study by Khan et al (1997) and hormone levels in this report].
At the mRNA level, Saad et al (1998) recently found no
significant differences in Cath D expression throughout the
menstrual cycle.
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Table 3 Characteristics of patients according to pS2 status
pS2
< 2.5 ng mg–1 ³ 2.5 ng mg–1 P-value
(n = 323) (n = 329)
ER
Mean 38.4 91.3 <0.0001
ER+ 170 (41) 248 (49)
ER– 153 (65) 81 (35) <0.0001
PgR
Mean 72.4 130.7 <0.0001
PgR+ 150 (35) 276 (65)
PgR– 173 (77) 53 (23) <0.0001
Cath D
Mean 8.4 15.2 0.01
SBRa
I 25 (37) 43 (63)
II 137 (46) 162 (54)
III 85 (52) 78 (48) 0.03
Hormonal status
Follicular 18 (32) 38 (68) NS*
Ovulatory 2 (22) 7 (78)
Luteal 24 (36) 44 (64)
Menopausal 279 (54) 240 (46) <0.001**
an = 530. *Chi-squared for trends between follicular, ovulatory and luteal
phases. **Chi-squared for trends between all subgroups.
Table 4 Characteristics of patients according to Cath D status
Cathepsin D
< 26 pmol mg–1 ³ 26 pmol mg–1 P-value
(n = 855) (n = 895)
ER
Mean 42 73 <0.01
ER+ 414 (41) 585 (59)
ER– 441 (59) 310 (41) <0.0001
PgR
Mean 64 111 <0.01
PgR+ 488 (44) 622 (56)
PgR– 367 (57) 273 (43) <0.0001
pS2a
Mean 8.4 15.2 0.01
SBRb
I 55 (57) 42 (43)
II 211 (54) 183 (46)
III 105 (42) 143 (58) <0.01
Hormonal status
Follicular 65 (48) 71 (52) NS*
Ovulatory 10 (36) 18 (64)
Luteal 87 (50) 88 (50)
Menopausal 693 (49) 718 (51) NS**
an = 652; bn = 739. *Chi-squared for trends between follicular, ovulatory and
luteal phases. **Chi-squared for trends between all subgroupsChanging levels of pS2 throughout the menstrual cycle and
menopause may be taken into account to more accurately predict
the hormone sensitivity and prognosis of a tumour. In this study,
the median value of pS2 (2.5 ng ml–1) was arbitrarily chosen as the
cut-off level. This threshold value is lower than the cut-off used in
some prognostic studies using the same radioimmunoassay,
ranging from 4 ng dl–1 to 11 ng dl–1 (Foekens et al, 1990; Gion et
al, 1993). However, when the mean value of pS2 (9.4 ng dl–1) was
set as a cut-off level, the increased level of pS2-positive tumours
in premenopausal women compared with post-menopausal women
was also observed (40% vs 22%, P < 0.0001, data not shown).
Further clinical studies with available follow-up are needed to
define which threshold is more reliable in predicting hormone
sensitivity and prognosis according to the hormonal status.
The findings of several studies assessing the effect of the
menstrual cycle phase at the time of surgery on prognosis have
been conflicting. Several studies (Badwe et al, 1991; Senie et al,
1991; Veronesi et al, 1994) and a meta-analysis (Fentiman et al,
1994) showed an increased overall survival rate in women with
breast cancer who had undergone surgery in the luteal phase. Other
studies, however, failed to demonstrate such a significant effect of
timing of surgery on prognosis (Powles et al, 1991; Rageth et al,
1991). Because no correlations were found between Cath D levels
and the menstrual phase, it is unlikely that hormonal induction of
total Cath D could explain the prognostic differences according to
the time of surgery. It is noteworthy that the effect of the menstrual
phase on steroid receptors and pS2 could potentially modify the
prediction of hormone sensitivity, and thus be a bias for the choice
of adjuvant hormone therapy. The population of the present study
is being prospectively analysed in order to study the prognostic
value of circulating sex hormone levels and the phase of the
menstrual cycle.
In conclusion, there are changes in pS2, but not Cath D levels, in
breast cancer during the menstrual cycle and menopause. This
suggests that interpretations of hormone dependency on the basis
of pS2 level should take the hormonal status at the time of surgery
into account. In contrast, it may not be necessary to consider the
hormonal status of the patients when using Cath D levels as a
marker of poor prognosis. Further clinical studies are needed to
define the appropriate pS2 cut-off level to be used relative to the
hormonal status at the time of surgery to improve predictive infor-
mation on prognosis and hormone responsiveness.
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